Volume : 12, Issue : 04, April – 2025
Title:
A COMPREHENSIVE REVIEW ON ORAL IN-SITU GEL FOR PERIODONTAL DISEASE
Authors :
Puri G. Ashutosh*, Atram C. Dr. Sandeep, Mandwe S. Vrushabh, Bhonde G. Akash, Bawankar V. Dipali
Abstract :
The current review on in situ gelling systems becomes one of the most popular and prominent.In-situ forming polymeric gelling systems has become prominent among novel drug delivery system (NDDS) in recent years due to advantages such as sustained and prolonged drug action, improved patient compliance and reduced frequency of administration of the drug in comparison to conventional drug delivery system (DDS). This is a type of mucoadhesive DDS where the polymeric formulation is in sol form before administration and once comes in contact with body fluids; it undergoes gelation to form a gel. The formulation of gel depends upon factors like temperature modulation, pH changes, presence of ions and ultraviolet irradiation from which drug gets released in sustained and controlled manner. Conventional formulation for the treatment of dental diseases has certain drawbacks. A new concept of in situ gel was develop to overcome the shortcoming of conventional formulation which deals with dental diseases. Conventional oral formulations like solution, suspension, and ointments have many disadvantages which result into poor bioavailability of drug in the buccal cavity. In-situ forming polymeric formulation drug delivery systems is in sol form before administration in the body, but once administered, undergoes gelation in-situ to form a gel.
There are several possible mechanisms that lead to in situ gel formation: solvent exchange, UV-irradiation, ionic cross-linkage, pH change, and temperature modulation. The article provides insight on natural polymers as well as synthetic polymers, including systems based on thermally triggered system, pH triggered system, ionic cross linking method, enzymatic cross linking method etc. Lastly, this review summarize about the characterization of oral in situ gels including different evaluation such as drug content study, pH & viscosity determination, texture analysis, spreadibility, gel strength, gelling time, sterility testing, in-vitro drug release study, stability study etc.
Key words: In-situ Dental Gel, Periodental diseases, Polymers , Periodontitis
Cite This Article:
Please cite this article in press Ashutosh G. Puri et al A Comprehensive Review On Oral In-Situ Gel For Periodontal Disease, Indo Am. J. P. Sci, 2025; 12(04).
Number of Downloads : 10
References:
1. Chavan P et al. Nasal drug delivery system: a review. World J Pharm and Pharma Sci., 2014; 3(12): 598-617.
2. Ramya DD et al. In-Situ Gelling System – Potential Tool For Improving Therapeutic Effects Of Drugs. Int J Pharm And Pharma Sci., 2013; 5(3): 27-30.
3. Bajpai V. In situ Gel Nasal Drug Delivery System – A Review. Int J Pharma Sci., 2014; 4: 577-580.
4. Aikawa K et al. Drug release from pH-response polyvinylacetal diethyl aminoacetate hydrogel and application to nasal delivery. Int J Pharm, 1998; 168: 181-8.
5. Almeida H et al. In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov Today, 2014; 19: 400–412.
6. Al-Shamklani A et al. Evaluation of the biological properties of alginates and gellan and xanthan gum. Proc Int Symp Control Release Bioact Mater, 1991; 18: 2134.
7. Bhardwaj TR et al. Natural gums and modified natural gums as sustained release carriers. Drug Devel Ind Pharm, 2000; 26: 1025-38.
8. Burkoth AK, Anseth KS. A review of photo crosslinked polyanhydrides: In situ forming degradable networks. Biomaterials, 2000; 21: 2395404.
9. Chand P et al. In situ gel: A Review. Indian J. Pharm. Biol. Res., 2016; 4(2): 11-19.
10. Chenite A et al. Novel injectable solution of chitosan form biodegradable gels in situ. Biomaterials, 2000; 21: 2155-61.
11. Priyanka B, Yogesh SC, Suresh K, et al. An Overview On Treatment Of Periodontal Disease. Asian Journal of Pharmacy and Medical Science. 2013; 3: 33-34.
12. Shankraiah M, Nagesh C, Venkatesh JS, et al. Sustained Release Device Containing Ornidazole For Periodontitis. International Research Journal Of Pharmacy. 2011; 2: 217-21.
13. Abdellaoui KS, Castioni NV, Gurny R. Local delivery of antimicrobial agents for the treatment of periodontal diseases. European Journal of Pharmaceutics and Biopharmaceutics. 2000: 83-93.
14. Sakshi A, Vidya D, Bhavna JK, et al. A comparative evaluation of efficacy of Punicagranatum and chlorhexidine on plaque and gingivitis. Journal of the International Clinical Dental Research Organization. 2011; 3: 29-32.
15. Pragati S, Ashok S, Kuldeep S. Recent Advances in Periodpontal Drug Delivery Systems. International Journal of Drug Delivery. 2009; 1: 1-14.
16. Tapash KG, William RPF. Drug Delivery to the oral Cavity, Molecule to Market, Drugs and the Pharmaceutical sciences. Taylor and Francis group. New York. 2005; 145: 211-30.
17. Pratik P, Ankur J, AK Sheth. Formulation and Evaluation of Sustained Release Chlorhexidine In Situ Gel for Periodontitis. An International Journal of Pharmaceutical Sciences. 2013; 4: 465-78.
18. Do M, Neut C, Metz H, Delcourt E, Mäder K, Siepmann J et al (2015) In-situ forming composite implants for periodontitis treatment: how the formulation determines system performance. Int J Pharm 486(1-2):38-51.
19. Agossa K, Lizambard M, Rongthong T, Delcourt-Debruyne E, Siepmann J, Siepmann F (2017) Physical key properties of antibiotic-free, PLGA/HPMC based in-situ forming implants for local periodontitis treatment. Int J Pharm 521(1-2):282–293.
20. Ranjan R, Patil SR, Veena H R (2017) Effect of in-situ application of simvastatin gel in surgical management of osseous defects in chronic periodontitis-a randomized clinical trial. J Oral Biol Craniofac Res 7(2):113 118.
21. Kassem AA, Ismail FA, Naggar VF, Aboulmagd E (2014) Comparative study to investigate the effect of meloxicam or minocycline HCl in situ gel system on local treatment of periodontal pockets. AAPS PharmSciTech 15(4):1021 1028.
22. Do MP, Neut C, Delcourt E, Seixas Certo T, Siepmann J, Siepmann F (2014) In situ forming implants for periodontitis treatment with improved adhesive properties. Eur J Pharm Biopharm 88(2):342–350.
23. Guo JH et al. Pharmaceutical applications of naturally occurring water-soluble polymers. Pharm Sci & Technol Today, 1998; 1: 254-61.
24. Haffajee AD, Socransky SS. Attachment level changes in destructive periodontal diseases. J Clin Periodontol, 1986; 13: 46-175.
25. Matanovic MR, Kristl J, Grabnar PA. Thermoresponsive polymers: insights into decisive hydrogel characteristics, mechanisms of gelation, and promising biomedical applications. Inter J Pharm 2014;472:262-75.
26. Coviello T, Matricardi P, Marianecci C, Alhaique F. Polysaccharide hydrogels for modified release formulations. J Controlled Release 2007;119:5-24.
27. Malafaya PB, Silva GA, Reis RL. Natural–origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications. Adv Drug Delivery Rev 2007;59:207-33.
28. Gil ES, Hudson SM. Stimuli-responsive polymers and their bio conjugates. Prog Polym Sci 2004;29:1173-222.
29. Gulrez SK, Al-Assaf S, Phillips GO. Hydrogels: methods of preparation, characterisation and applications. Progress in molecular and environmental bioengineering from analysis and modelling to technology applications; 2011. p. 117-50.
30. Radivojsa M, Grabnar I, Grabnar PA. Thermo-reversible in situ gelling poloxamer-based systems with chitosan nanocomplexes for prolonged subcutaneous delivery of heparin: design and in vitro evaluation. Eur J Pharm Sci 2013;50:93-101.
31. Ismail FA et al. In situ gel formulation for gene delivery: release and myotoxicity studies. Pharm Dev Technol, 2000; 5: 391-7.
32. Kant A et al. In situ gelling system – an overview. Pharmacologyonline, 2011; 2: 28-44.
33. Kashyap N et al. Design and evaluation of biodegradable, biosensitive in situ gelling systems for pulsatile delivery of insulin. Biomaterials, 2007; 28: 2051-60.
34. Kawasaki N et al. Thermally reversible xyloglucan gels as vehicles for oral drug delivery. Int J Pharm, 1999; 181: 227-34.
35. Kempe S, Mader K. In situ forming implants – an attractive formulation principle for parenteral depot formulations. J Cont Release, 2012; 161: 668–679.
36. Kumar S, Himmelstein K. Modification of in-situ gel behaviour of Carbopol solutions by hydroxypropylmethylcellulose. J Pharm Sci., 1995; 84: 344-8.
37. Miyazaki S et al. In situ gelling gellan formulations as vehicles for oral drug delivery. J Control Rel., 1999; 60: 287-95.
38. Miyazaki S et al. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm, 2001; 229: 29-36.
39. Miyazaki S et al. Thermally reversible xyloglucan gels as vehicles for rectal drug delivery. J Control Rel., 1998; 56: 75-83.
40. Miyazaki S, Kawasaki N. Comparison of in situ gelling formulations for the oral delivery of cimetidine. Int J Pharm, 2001; 220: 161-8.
41. Motto F et al. In-vitro assessment of new embolic liquids prepared from preformed polymers and water miscible solvents aneurysm treatment. Biomaterials, 2000; 21: 803-11.
42. Nirmal HB et al. In situ gel: New trends in controlled and sustained drug delivery system. Int J PharmTech Res., 2010; 2(2): 1398408.
43. Pagar SA et al. A Review on Intranasal Drug Delivery System. J Adv Pharm Educ & Res., 2013; 3(4): 333-346.
44. Podual K et al. Dynamic behavior of glucose oxidase-containing microparticles of poly(ethylene)- grafted cationic hydrogels in an environment of changing pH. Biomaterials, 2000; 21: 1439-50.
45. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev., 2001; 53: 321-39.
46. Rehaman S et al. Site Specific Delivery System for the treatment of Periodontitis. Ind J Pharma Sci March-April, 2003; 106 – 112.
47. Riva R et al. Chitosan and chitosan derivatives in drug delivery and tissue engineering. In: Jayakumar R, Prabaharan M, Muzzarelli RAA. Chitosan for biomaterials II. Berlin: Springer-Verlag Berlin, 2011; 19–44.
48. Sawhney AS et al. Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled release carriers. US Patent 5410016. 1995.
49. Sechoy O et al. A new long acting ophthalmic formulation of carteolol containing Alginic acid. Int J Pharm, 2000; 207: 109-16.
50. Soppimath KS et al. Stimulus-responsive “smart” hydrogels as novel drug delivery systems. Drug Dev Ind Pharm, 2002; 28: 957-74.
51. Suisha F et al. Xyloglucan gels as sustained release vehicles for intraperitoneal administration of mitomycin C. Int J Pharm, 1998; 172: 27-32.
52. Swamy NGN, Zaheer A. Mucoadhesive In situ Gels as Nasal Drug Delivery Systems: An Overview. Asian J Pharma Sci., 2012; 7(3): 168-180.
53. Vyas SP et al. Controlled and targeted drug delivery strategies towards intra-periodontal pocket diseases. J Clin Pharm Ther, 2000; 25: 21-42.
54. Sarada K, Firoz S, Padmini K. In-situ gelling system: a review. Int J Curr Pharma Rev Res2014;15:76-90.
55. Yadav KS, Rajpurohit R, Sharma S. Glaucoma: current treatment and impact of advanced drug delivery systems. Life Sci 2019;221:362-76.
56. Kakinoki S, Taguchi T. Antitumor effect of an injectable in-situ forming drug delivery system composed of a novel tissue adhesive containing doxorubicin hydrochloride. Eur J Pharm Biopharm 2007;67:676-81.
57. Miyazaki S, Kubo W, Itoh K, Konno Y, Fujiwara M, Dairaku M, et al. The effect of taste masking agents on in situ gelling pectin formulations for oral sustained delivery of paracetamol and ambroxol. Int J Pharm 2005;297:38-49.
58. Dhir S, Ali Saffi K, Kamalpuria N, Mishra D. An overview of in situ gelling system. Int J Pharm Life Sci 2016;7:5135-56.
59. Van Tomme SR, Hennink WE. Biodegradable dextran hydrogels for protein delivery applications. Expert Rev Med Devices 2007;4:147-64.
60. Basu A, Kunduru KR, Doppalapudi S, Domb AJ, Khan W. Poly (lactic acid) based hydrogels. Adv Drug Delivery Rev 2016;107:192-205.
61. Kubo W, Itoh K, Miyazaki S, Attwood D. Oral sustained delivery of theophylline and cimetidine from in situ gelling pectin formulations in rabbits. Drug Dev Ind Pharm 2005;31:819-25.
62. Soni V, Pandey V, Tiwari R, Asati S, Tekade RK. Design and evaluation of ophthalmic delivery formulations. In: Basic FundamentalsofDrugDelivery,AcademicPress;2019.p.473-538.
63. Rao MA. Measurement of flow and viscoelastic properties. In: Rheology of Fluid, Semisolid, and Solid Foods, Springer, Boston, MA;2014.p. 63-159.
64. Wortel V, Taelman MC, Roschzttardtz F, Tharwat F. Tadros, Sandra Léonard, Cornelis Verboom. Colloid Stability; 2007.
65. Wang XQ et al. In situ gel-forming system: an attractive alternative for nasal drug delivery. Crit Rev Ther Drug Carrier Syst, 2013; 30: 411-434.
66. Yeom RH et al. Periodontal diseases. J Periodontal diseases, 1998; 68: 1102.
67. Bashir R, Majeed A, Ali T, Farooq S, Khan NA. Floating oral in situ gel: a review. J Drug Delivery Ther 2019;9:442-8.
68. Majeed A, Khan NA. Ocular in situ gel: an overview. J Drug Delivery Ther 2019;9:337-47.
69. Soliman KA, Ullah K, Shah A, Jones DS, Singh TR. Poloxamer based in situ gelling thermoresponsive systems for ocular drug delivery applications. Drug Discovery Today 2019;24:1575-86.
70. Kumbhar AB, Rakde AK, Chaudhari PD. In situ gel forming injectable drug delivery system. Int J Pharm Sci Res 2013;4:597-609.
71. Pandya Y, Sisodiya D, Dashora K. Atrigel, implants and controlled released drug delivery system. Int J Biopharm 2014;5:208-13.
72. Mammo ZN, Flanagan JG, James DF, Trope GE. Generic versus brand-name North American topical glaucoma drops. Can J Ophthalmol 2012;47:55-61.
73. Dhirajkumar KC, Sushilkumar SP. Current Status of Ophthalmic In-situ Forming Hydrogel. International Journal of Pharma and Bio Sciences. 2012; 3: 372-388.